Cytoreductive nephrectomy in the era of targeted therapies: a review

In the pre‐targeted therapy era, palliative cytoreductive nephrectomy combined with cytokine immunotherapy was the standard treatment protocol for the management of metastatic renal cell carcinoma. The introduction of targeted therapies has improved response rates, median survival and overall prognosis when compared to immunotherapy. The role of cytoreductive nephrectomy in providing an independent survival advantage when used alongside immunotherapy has been demonstrated by two randomised controlled trials. However, with the new shift in improved treatment outcomes from cytokine immunotherapy to targeted therapies, the continuing role of cytoreductive nephrectomy as a viable surgical treatment method remains controversial.

[1]  K. Bensalah,et al.  European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma , 2016 .

[2]  S. Barni,et al.  Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis. , 2016, Clinical genitourinary cancer.

[3]  Arun Z. Thomas,et al.  The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma , 2016, Therapeutic advances in urology.

[4]  T. Wilt,et al.  Immunotherapy for advanced renal cell cancer. , 2015, The Cochrane database of systematic reviews.

[5]  D. McDermott,et al.  Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma , 2015, Therapeutic advances in urology.

[6]  A. Ravaud,et al.  CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. , 2015 .

[7]  T. Choueiri,et al.  The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. , 2015, The Lancet. Oncology.

[8]  C. Gross,et al.  The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization. , 2015, Urology.

[9]  R. Madan,et al.  Metastatic papillary renal cell carcinoma regression after cytoreductive nephrectomy. , 2015, Urology.

[10]  T. Choueiri,et al.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, European urology.

[11]  J. Brooks,et al.  Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era , 2014, International journal of cancer.

[12]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[13]  Samuel K. Park,et al.  Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study. , 2013, Urology.

[14]  T. Choueiri,et al.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. , 2013, The Lancet. Oncology.

[15]  B. Ljungberg.  The Role of Metastasectomy in Renal Cell Carcinoma in the Era of Targeted Therapy , 2013, Current Urology Reports.

[16]  B. Escudier,et al.  Emerging immunotherapies for renal cell carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  B. Győrffy,et al.  A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma , 2012, Current cancer drug targets.

[18]  G. Peters,et al.  TRAIL-induced pro- and anti-apoptotic kinase activation in Non small cell lung cancer cells , 2012 .

[19]  C. Blank,et al.  A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. , 2011, Urology.

[20]  D. Berney,et al.  The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. , 2011, European urology.

[21]  Snehal,et al.  甲状腺癌手术——Memorial Sloan-Kettering Cancer Center经验（一） , 2011 .

[22]  S. Boorjian,et al.  Survival after complete surgical resection of multiple metastases from renal cell carcinoma , 2011, Cancer.

[23]  R. Abaza.  Initial series of robotic radical nephrectomy with vena caval tumor thrombectomy. , 2011, European urology.

[24]  B. Rini,et al.  Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma , 2011, Cancer.

[25]  D. Berney,et al.  The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  B. Lane,et al.  Association of percentage of tumour burden removed with debulking nephrectomy and progression‐free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy , 2010, BJU international.

[27]  E. Small,et al.  Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Bhat.  Role of surgery in advanced/metastatic renal cell carcinoma , 2010, Indian journal of urology : IJU : journal of the Urological Society of India.

[29]  E. Wallen,et al.  Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  E. Klein,et al.  Surgical resection of renal cell carcinoma after targeted therapy. , 2009, The Journal of urology.

[31]  Apurva A Desai,et al.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Russo,et al.  Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. , 2008, The Journal of urology.

[33]  R. Motzer,et al.  Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[35]  F. Guillé,et al.  Cytoreductive nephron‐sparing surgery does not appear to undermine disease‐specific survival in patients with metastatic renal cell carcinoma , 2007, Cancer.

[36]  J. Hainsworth,et al.  Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial. , 2007, Clinical genitourinary cancer.

[37]  B. Rini,et al.  The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. , 2007, The Journal of urology.

[38]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[39]  R. Figlin,et al.  Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy? , 2007, Clinical Cancer Research.

[40]  W. Kaelin.  The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma , 2007, Clinical Cancer Research.

[41]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[42]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[43]  C. Lohse,et al.  The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. , 2006, The Journal of urology.

[44]  M. Meng,et al.  Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. , 2006, Journal of endourology.

[45]  J. Lam,et al.  Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery , 2005, BJU international.

[46]  J. Hainsworth,et al.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  C. Tangen,et al.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.

[48]  J. Lam,et al.  Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. , 2005, The Journal of urology.

[49]  G. Mickisch,et al.  Combination of surgery and immunotherapy in metastatic renal cell carcinoma , 2005, World Journal of Urology.

[50]  J. Kaouk,et al.  Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma , 2004, BJU international.

[51]  J. Lam,et al.  Changing concepts in the surgical management of renal cell carcinoma. , 2004, European urology.

[52]  S. Campbell,et al.  Metastatic renal cell carcinoma , 2003, Current treatment options in oncology.

[53]  Mihir M Desai,et al.  Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. , 2003, The Journal of urology.

[54]  William C Hahn,et al.  Rules for making human tumor cells. , 2002, The New England journal of medicine.

[55]  E. T. Gawlinski,et al.  The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomy. , 2002, Cancer research.

[56]  G. Freeman,et al.  The B7–CD28 superfamily , 2002, Nature Reviews Immunology.

[57]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[58]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[59]  R. Clayman,et al.  Laparoscopic radical/total nephrectomy: a decade of progress. , 2001, Journal of endourology.

[60]  M. Atkins,et al.  Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. , 1997, The Journal of urology.

[61]  J. Dutcher,et al.  Cytoreductive surgery for stage IV renal cell carcinoma. , 1995, The Journal of urology.

[62]  R. Fisher,et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  P. Choyke,et al.  Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy. , 1993, The Journal of urology.

[64]  Louis R Kavoussi,et al.  Laparoscopic Nephrectomy: Initial Case Report. , 1991, The Journal of urology.

[65]  P. Schellhammer,et al.  Spontaneous regression of metastatic renal cell carcinoma. , 1982, Urology.

[66]  S. Freed,et al.  Idiopathic regression of metastases from renal cell carcinoma. , 1977, The Journal of urology.

[67]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[68]  Lorenzo Marconi,et al.  Guidelines on Renal Cell Carcinoma , 2007 .

[69]  E. Klein,et al.  Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.